Start Here

Pillars

Practice — how to do it Science — research The Root — origin & lineage Member Stories — first-person What We Reject — our lines The Mycelium — news
Browse Everything FAQ Dictionary Manifesto
Connect Contact

The Mycelium

The Imperial College Body of Work: What It Has Shown and What It Hasn't

For more than a decade, the Centre for Psychedelic Research at Imperial College London has produced some of the most-cited psilocybin studies in the modern literature. A careful look at what the research actually demonstrates, where the field has oversold it, and what questions the next decade needs to answer.

By The Microdose Movement ·

If you have read a news article about psilocybin in the last ten years, there is roughly a fifty percent chance that the study it cited came out of Imperial College London. Since 2014, the Centre for Psychedelic Research at Imperial — built initially around the work of Robin Carhart-Harris and later expanded under David Nutt, Mendel Kaelen, Rosalind Watts, and a growing faculty — has produced more peer-reviewed psilocybin research per year than almost any other lab on earth. Their work has shaped the clinical conversation, the neuroscience conversation, and the cultural conversation in roughly equal measure.

It is also a body of work that deserves to be read carefully rather than quoted selectively, and the cultural conversation has not always been careful with it. What follows is an honest attempt at a critical read: what the Imperial body of work has actually shown, where it has been overclaimed, and what questions the next decade of research needs to answer before the early enthusiasm hardens into something that will outlive the evidence.

What the Imperial work has shown

Start with what the research solidly supports.

Psilocybin reliably produces a specific neural signature. The Imperial fMRI studies — beginning with the 2012 Carhart-Harris paper in PNAS and continuing through the more recent EEG and connectivity work — have consistently shown that psilocybin alters functional connectivity in the brain in a characteristic way. Activity in the default mode network, the set of brain regions active during self-referential thinking and mind-wandering, is reduced. Communication between brain regions that normally do not talk to each other increases. The brain becomes, in the researchers’ phrase, “hyperconnected” during the acute experience. This is a real and replicated finding, and it is one of the more robust things we know about what psilocybin does to the brain in real time.

Psilocybin produces substantial antidepressant effects in a subset of patients with treatment-resistant depression. The Imperial open-label psilocybin trial for treatment-resistant depression, published in 2016 and followed by larger and more controlled studies through 2021 and 2022, found that a majority of participants experienced meaningful reductions in depression symptoms after two high-dose psilocybin sessions combined with psychotherapy. The effects, in many cases, were larger than what is typically achieved with conventional antidepressants, and some participants maintained improvements at the six-month follow-up. This is a genuinely important result and it is part of why the psilocybin-for-depression story became the flagship of the modern psychedelic research wave.

Psilocybin experiences appear to open a window of increased psychological flexibility. The Imperial work on what the researchers call “psychological insight” — the capacity to see one’s own patterns, beliefs, and behaviors from a new angle — has consistently found that this is a core mechanism of the therapeutic response. The molecule does not, by itself, fix depression. What it seems to do is create a period of unusual openness during which the psychotherapy that accompanies the session can land in a way it could not before. The medicine is the opening. The therapy is what walks through.

Psilocybin has, in these trials, a strong acute safety profile. Serious adverse events are rare. Most participants tolerate the experience physiologically without difficulty. Common side effects — nausea, headache, emotional intensity — are manageable and short-lived. This is worth saying clearly because the public conversation sometimes conflates psilocybin with drugs that carry much higher acute medical risk.

Those are the solid findings. They are enough, on their own, to justify the continued investment of serious research attention.

Where the field has oversold it

Now the careful part.

The trials are small. The foundational Imperial depression study (2016) enrolled twelve participants. Later studies enrolled dozens, not hundreds. The largest recent psilocybin depression trial — not from Imperial, but from Compass Pathways, and following a similar protocol — enrolled 233 participants, which is respectable but still small by the standards of psychiatric drug approval. When you read “psilocybin is more effective than standard antidepressants,” the “more effective” is based on sample sizes that would be considered preliminary for most drug approval processes. This does not mean the effect is not real. It means the confidence we should place in the size of the effect is lower than the public conversation often implies.

The placebo problem is not solved. Psychedelic trials face an unusual methodological challenge: participants generally know whether they have received the active drug or the placebo. (A participant who has taken 25mg of psilocybin has no doubt they are on the active arm.) This “functional unblinding” means that some of the reported benefits may be attributable to expectancy effects — the participant believes something transformative has happened, and the belief itself produces some of the improvement. Researchers have tried various workarounds, including active placebos like low-dose methylphenidate or niacin, but none of these fully solve the problem. The Imperial researchers themselves have written extensively about this, and they deserve credit for doing so. The broader cultural conversation has been less honest about it.

The durability question is still open. The early studies reported impressive six-month follow-up data, but longer-term follow-ups have been more mixed. Some participants sustain the improvements for years. Others relapse and need additional sessions. The clean narrative of “two sessions and you are done” is not what the longer-term data actually show. The more accurate narrative is that psilocybin therapy appears to produce a meaningful window of improvement, the length and stability of which varies substantially between individuals, and which in many cases benefits from ongoing supportive care.

The psychotherapy is doing a lot of the work. The Imperial protocols involve multiple preparation sessions, supervised dosing days with trained guides, and post-session integration therapy with experienced clinicians. The amount of high-quality therapeutic attention the participants receive is extraordinary — it is more therapy, delivered by more skilled clinicians, than most depressed people ever see in their lifetimes. It is genuinely unclear how much of the observed benefit is attributable to the psilocybin itself versus to the therapy-plus-psilocybin combination. This is a well-known issue in the field and the researchers have discussed it openly. What it means is that “psilocybin works” is probably shorthand for “psilocybin combined with intensive therapy works, and we do not yet know how much of the work is being done by each component.”

Microdosing is a separate question. Most of the Imperial work has been on single or dual high-dose psilocybin sessions, not on sub-perceptual microdosing protocols. The microdosing literature is much thinner and the evidence base for microdosing-specific claims is much weaker. When microdosing brands cite Imperial research to support their practice, they are usually citing high-dose research and extrapolating, which is a stretch the research itself does not endorse. The Imperial team has, in recent years, begun publishing more on microdosing, and the early results have been notably mixed — some studies find modest benefits, some find results indistinguishable from placebo, and some find benefits that appear to be largely attributable to expectancy effects. The microdosing picture from the Imperial literature is “interesting but unresolved,” not “proven.”

What the next decade needs

Here is a short list of the questions that would move the field from “promising early research” to “mature body of knowledge.”

Larger trials with better blinding. The next wave of psilocybin trials needs to enroll thousands of participants, not dozens, and needs to develop better strategies for managing the functional-unblinding problem. Active placebos, specialized blinding protocols, and clever study designs that separate the acute experience from the longer-term outcome are all avenues being explored.

Head-to-head comparisons. Most psilocybin trials compare psilocybin-plus-therapy to waitlist or to a weaker form of care. The research we actually need is psilocybin-plus-therapy versus best-available conventional care (SSRIs, CBT, or both) with matched therapeutic intensity on both arms. Only then can we say whether the psilocybin is doing work that the therapy alone could not have done.

Subgroup analysis. Psilocybin does not work for everyone. Some participants in the trials do not respond at all. Identifying who responds, who does not, and why is essential before clinicians can responsibly prescribe it. The predictors matter: personality factors, baseline openness, specific depression subtypes, trauma history, and genetic factors may all play roles. The Imperial team has begun this work and it is some of the most important research in the pipeline.

Longer-term durability studies. Two-year, five-year, and ten-year follow-ups are needed to tell us whether the benefits of psilocybin therapy are lasting or whether they fade without reinforcement. These studies are expensive and slow and absolutely necessary.

Separate tracks for microdosing. The microdosing question deserves its own research program, designed specifically around sub-perceptual dosing rather than piggybacking on the high-dose literature. Early indications are that microdosing may have real but modest effects, or may largely be an expectancy-driven practice, or may work for some subgroups and not others. We do not know yet. Saying so honestly is the ground on which better research gets built.

What this means for the Movement

The Movement’s position on the Imperial body of work is that it is valuable, honest, and appropriately critical of its own limits, and that the field’s broader interpretation of the Imperial research has not always been as careful as the research itself. The researchers deserve credit. The headline writers often do not.

What the research supports, at this point in 2026, is the following: psilocybin is a real pharmacological intervention with real neural effects that can produce meaningful improvements in depression symptoms when combined with skilled psychotherapy in structured settings. That is a sentence worth pausing on because it is both cautious and significant. It is also a different sentence than “psilocybin cures depression.”

The microdosing practice that we care about most is not the clinical high-dose therapy that most Imperial research has studied. It is something gentler, more diffuse, more integrated into daily life, and it has a thinner evidence base. That does not make it wrong. It means that what we have to say about microdosing has to be grounded in lived experience, careful self-observation, and the honest admission that the research is still catching up. That is a harder story to tell than “the research proves it.” It is also the only story that will survive being tested.

The Movement’s commitment is to tell the true story about this practice, even when the true story is more complicated than the one that would get more clicks. The Imperial work gives us part of the picture. The rest of it is still being assembled, one trial at a time, one careful experiment at a time, one honest admission of uncertainty at a time. The next decade is going to tell us more. We are in no rush to get ahead of what it actually says.

Sources and Further Reading

The Microdose Movement is an educational community, not a medical provider. Nothing in this article is medical advice. We are not affiliated with Imperial College London or the Centre for Psychedelic Research. This is editorial analysis of publicly available peer-reviewed research, current as of April 2026.